NCT00626873View on ClinicalTrials.gov

Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Ovarian Cancer
Interventions
DRUG

Definity

Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.

OTHER

medical chart review

Trial Locations (3)

37064

Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville

Vanderbilt-Ingram Cancer Center at Franklin, Nashville

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT00626873 - Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary | Biotech Hunter | Biotech Hunter